New Chronic Inflammatory Demyelinating Polyneuropathy Findings from University of Turin Described (Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain Related to Chronic Inflammatory Demyelinating Polyneuropathy: A...).

A recent study conducted by researchers at the University of Turin in Italy explored the use of ultramicronized Palmitoylethanolamide (umPEA) in managing neuropathic pain related to chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a rare autoimmune disease characterized by peripheral inflammation and neuropathic pain. The study involved 14 CIDP patients who were already undergoing immunoglobulin therapy. The results showed that the addition of umPEA to immunoglobulins significantly improved neuropathic pain symptoms and quality of life for the patients. The study suggests that umPEA could be a safe and effective treatment option for managing neuropathic pain in CIDP patients, and it highlights the importance of neuroinflammation modulation in the management of CIDP's painful symptoms. [Extracted from the article]